These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 33262816)

  • 1. Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites.
    Kawaratani H; Moriya K; Namisaki T; Shimozato N; Kaji K; Takaya H; Fujinaga Y; Sawada Y; Sato S; Saikawa S; Kubo T; Akahane T; Fukui H; Yoshiji H
    Exp Ther Med; 2021 Jan; 21(1):30. PubMed ID: 33262816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial.
    Tang J; Wang Y; Han T; Mao Q; Cheng J; Ding H; Shang J; Zhang Q; Niu J; Ji F; Chen C; Jia J; Jiang X; Lv N; Gao Y; Wang Z; Wei Z; Chen Y; Zeng M; Mao Y
    BMC Gastroenterol; 2020 Nov; 20(1):391. PubMed ID: 33213378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive parameter of tolvaptan effectiveness in cirrhotic ascites.
    Kawaratani H; Fukui H; Moriya K; Noguchi R; Namisaki T; Uejima M; Kitade M; Takeda K; Okura Y; Kaji K; Nishimura N; Takaya H; Aihara Y; Sawada Y; Sato S; Seki K; Mitoro A; Yamao J; Yoshiji H
    Hepatol Res; 2017 Aug; 47(9):854-861. PubMed ID: 27704665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Validation of a Patient-Reported Outcome Measurement for Symptom Assessment in Cirrhotic Ascites.
    Neijenhuis M; Gevers TJG; Atwell TD; Gunneson TJ; Schimek AC; Kievit W; Drenth JPH; Kamath PS
    Am J Gastroenterol; 2018 Apr; 113(4):567-575. PubMed ID: 29557942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of peritoneovenous shunt for treating tolvaptan-resistant refractory ascites in a cirrhotic patient with portal vein thrombosis: A case report.
    Shigeto K; Kawaguchi T; Niizeki T; Kunitake Y; Takedatsu H; Tonan T; Fujimoto K; Tanaka M; Abe T; Naito H; Torimura T
    Oncol Lett; 2016 May; 11(5):3205-3209. PubMed ID: 27123091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolvaptan in Chinese cirrhotic patients with ascites: A randomized, placebo-controlled phase 2 trial.
    Wang YF; Tang JT; Han T; Ding HG; Ye WJ; Wang MR; Cheng J; Yang YP; Chen CW; Xie Q; Mao Q; Niu JQ; Wang ZH; Wei Z; Chen YX; Zeng M; Mao YM
    J Dig Dis; 2018 Mar; 19(3):144-154. PubMed ID: 29389068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema.
    Sakaida I; Yamashita S; Kobayashi T; Komatsu M; Sakai T; Komorizono Y; Okada M; Okita K;
    J Int Med Res; 2013 Jun; 41(3):835-47. PubMed ID: 23685892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Copeptin and Zinc-α2-glycoprotein Levels Are Novel Biomarkers of Tolvaptan Treatment in Decompensated Cirrhotic Patients with Ascites.
    Shigefuku R; Iwasa M; Eguchi A; Tempaku M; Tamai Y; Suzuki T; Takei Y
    Intern Med; 2021; 60(21):3359-3368. PubMed ID: 34719623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolvaptan for the treatment of liver cirrhosis oedema.
    Sakaida I
    Expert Rev Gastroenterol Hepatol; 2014 Jul; 8(5):461-70. PubMed ID: 24678622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors of the pharmacological action of tolvaptan in patients with liver cirrhosis: a post hoc analysis.
    Sakaida I; Terai S; Nakajima K; Shibasaki Y; Tachikawa S; Tsubouchi H
    J Gastroenterol; 2017 Feb; 52(2):229-236. PubMed ID: 27379386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to tolvaptan and its effect on prognosis in cirrhotic patients with ascites.
    Kogiso T; Yamamoto K; Kobayashi M; Ikarashi Y; Kodama K; Taniai M; Torii N; Hashimoto E; Tokushige K
    Hepatol Res; 2017 Aug; 47(9):835-844. PubMed ID: 27670393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study.
    Shiba S; Chu PS; Nakamoto N; Yamataka K; Taniki N; Ojiro K; Yamaguchi A; Morikawa R; Yoshida A; Ikura A; Ebinuma H; Saito H; Kanai T
    BMC Gastroenterol; 2020 Mar; 20(1):53. PubMed ID: 32138675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of continued administration of tolvaptan on cirrhotic patients with ascites.
    Kogiso T; Sagawa T; Kodama K; Taniai M; Tokushige K
    BMC Pharmacol Toxicol; 2018 Dec; 19(1):87. PubMed ID: 30563565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic effects of short- and intermediate-term tolvaptan administration for refractory ascites in patients with advanced liver cirrhosis.
    Akiyama S; Ikeda K; Sezaki H; Fukushima T; Sorin Y; Kawamura Y; Saitoh S; Hosaka T; Akuta N; Kobayashi M; Suzuki F; Suzuki Y; Arase Y; Kumada H
    Hepatol Res; 2015 Nov; 45(11):1062-70. PubMed ID: 25429910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia.
    Wang S; Zhang X; Han T; Xie W; Li Y; Ma H; Liebe R; Weng H; Ding HG
    BMC Gastroenterol; 2018 Sep; 18(1):137. PubMed ID: 30180806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio.
    Komiyama Y; Kurosaki M; Nakanishi H; Takahashi Y; Itakura J; Yasui Y; Tamaki N; Takada H; Higuchi M; Gotou T; Kubota Y; Takaura K; Hayashi T; Oh W; Okada M; Enomoto N; Izumi N
    PLoS One; 2017; 12(3):e0174649. PubMed ID: 28362879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Close correlation between urinary sodium excretion and response to tolvaptan in liver cirrhosis patients with ascites.
    Uojima H; Kinbara T; Hidaka H; Sung JH; Ichida M; Tokoro S; Masuda S; Takizawa S; Sasaki A; Koizumi K; Egashira H; Kako M
    Hepatol Res; 2017 Mar; 47(3):E14-E21. PubMed ID: 27059410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protocol to evaluate the efficacy and safety of tolvaptan in patients with refractory ascites after liver resection: an open-label, single-arm phase I/II study.
    Namba Y; Kobayashi T; Kuroda S; Hashimoto M; Takei D; Fukuhara S; Oshita K; Matsubara K; Honmyo N; Nakano R; Sakai H; Tahara H; Ohira M; Ide K; Ohdan H
    Int J Surg Protoc; 2024 Mar; 28(1):1-5. PubMed ID: 38433869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of tolvaptan non-responders and outcomes of tolvaptan treatment of ascites.
    Iwamoto T; Maeda M; Saeki I; Hidaka I; Tajima K; Ishikawa T; Takami T; Sakaida I
    J Gastroenterol Hepatol; 2019 Jul; 34(7):1231-1235. PubMed ID: 30370940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis.
    Tajiri K; Tokimitsu Y; Ito H; Atarashi Y; Kawai K; Minemura M; Yasumura S; Takahara T; Shimizu Y; Sugiyama T
    Dig Dis; 2018; 36(4):314-321. PubMed ID: 29852495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.